Effects of mifepristone on endometrial receptivity.
At the development of receptivity the endometrium undergoes specific changes. Several factors have been suggested as markers of endometrial receptivity. A common feature for most of these factors is that they are directly, or indirectly, regulated by progesterone. The effect of various doses and regimens of mifepristone on endometrial development and markers of receptivity has been studied. Timed endometrial biopsies were assessed by immunhistochemistry, reverse transcriptase polymerase chain reaction (RT-PCR) and electron microscopy. In addition the contraceptive efficacy of these regimens was investigated. Administration of 200 mg of mifepristone immediately post ovulation has a pronounced effect on endometrial development and on suggested markers of receptivity. This regimen has been shown to be an effective contraceptive method. When 10 mg is given pre or post ovulation, only minor effects on the endometrium are observed. Our studies show that mifepristone, when administered in low doses that do not affect ovulation, significantly affects some of the studied markers of endometrial receptivity and reduces pregnancy rates; however, these activities are more pronounced with the higher dose, which is more effective. Our findings provide insight into the regulation of progesterone receptors of various suggested markers of endometrial receptivity and the possibility of using mifepristone for endometrial contraception.
Danielsson
Kristina Gemzell
KG
Department of Woman and Child Health, Division for Obstetrics and Gynecology, Karolinska Hospital/Institute, Stockholm S-171 76, Sweden. kristina.gemzell@kbh.ki.se
Marions
Lena
L
Bygdeman
Marc
M
D003267:Contraception; D003280:Contraceptives, Oral, Synthetic / Q000494:pharmacology; D004717:Endometrium / Q000187:drug effects*; D005187:Fallopian Tubes / Q000187:drug effects; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D008854:Microscopy, Electron; D015735:Mifepristone / Q000494:pharmacology*; D010060:Ovulation / Q000187:drug effects; D011374:Progesterone / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
D003280:Contraceptives, Oral, Synthetic; D006727:Hormone Antagonists; D011980:Receptors, Progesterone; D015735:Mifepristone; D011374:Progesterone